By Blake Brittain (Reuters) -British pharmaceutical giant GlaxoSmithKline and rival Pfizer have agreed to end a lawsuit that ...

As the respiratory syncytial virus (RSV) vaccine field grapples with a significantly reduced market size thanks to regulatory ...

GSK Plc and Pfizer Inc. settled a patent-infringement lawsuit over competing vaccines for RSV, ending the dispute in Delaware ...

The European Commission approved Pfizer's respiratory syncytial virus vaccine for the prevention of lower respiratory tract ...

GlaxoSmithKline (NYSE:GSK) and Pfizer (NYSE:PFE) have agreed to dismiss a U.S. patent lawsuit over Pfizers RSV vaccine, ...

Just hours after thousands of U.S. Food and Drug Administration employees were shown the door, Barclay Butler, the agency’s ...

Pfizer (NYSE:PFE) recently saw the European Commission expand the authorization for its RSV vaccine, ABRYSVO, to include ...

In recent developments, a class action lawsuit was filed against Cerevel Therapeutics, Bain Capital Investors, and Pfizer ...

The bivalent respiratory syncytial virus prefusion F vaccine is highly effective and well tolerated against RSV-associated ...

Lastly, Pfizer is a solid dividend stock. It now offers a beefy 6.8% yield, and has increased its payouts by 53.6% in the ...

In the prefusion state, the RSV fusion protein (F) is a major target of neutralizing antibodies, serving as the basis of Pfizer’s RSV vaccine. Variations in the F protein sequence among RSV-A ...

Pfizer (NYSE:PFE) and GSK (NYSE:GSK) on Thursday agreed to end a patent lawsuit over claims that the former’s vaccine, ...